Diffuse Large B-Cell Lymphoma
|
0.600 |
CausalMutation
|
disease |
CGI |
|
|
|
Diffuse Large B-Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our findings highlight the important role of cAMP signaling in DLBCL and suggest that clinically relevant PDE4 and PI3K/AKT inhibitors might be useful in the treatment of DLBCL and additional B-lymphoid malignancies with increased PDE4B expression.
|
15331441 |
2005 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
PIK3CA mutations in exons 9 and 20 were investigated in 76 primary human DLBCLs, 3 DLBCL cell lines (LY1, LY8, and LY10), and 9 related samples using polymerase chain reaction-based sequence analysis to assess the possible relevance of PIK3CA mutations in DLBCL to the PI3K/AKT pathway activation.
|
18382359 |
2008 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
This work suggests that multilevel inhibition of the PI3K/Akt/mTOR pathway and double-block of cell cycle progression are effective strategies for DLBCL therapy.
|
19223503 |
2009 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Leptin receptor expression and its association with PI3K/AKT signaling pathway in diffuse large B-cell lymphoma.
|
20443680 |
2010 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
These results demonstrate a critical function of PI3K-PDK1 signaling upstream of MALT1 protease and NF-κB in distinct ABC DLBCL cells and provide a rationale for the pharmacologic use of PI3K inhibitors in DLBCL therapy.
|
21173233 |
2011 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
These results demonstrate a critical function of PI3K-PDK1 signaling upstream of MALT1 protease and NF-κB in distinct ABC DLBCL cells and provide a rationale for the pharmacologic use of PI3K inhibitors in DLBCL therapy.
|
21173233 |
2011 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Taken together, our results reveal a novel target involved in miR-155 biological characteristics and provide a molecular link between the overexpression of miR-155 and the activation of PI3K-AKT in DLBCL.
|
22609116 |
2012 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling is frequently dysregulated in diffuse large B cell lymphoma (DLBCL) including the favorable germinal centre B-cell (GCB) and the unfavorable activated B-cell (ABC) subtypes. mTOR promotes cap-dependent translation of proteins, like Mcl-1, through inhibitory phosphorylation of the eukaryotic translation initiation factor 4E binding protein 1 (4EBP1).
|
23200668 |
2013 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In this study, expression of the important components of the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway and their clinical significance were investigated in 73 DLBCL cases.
|
23636313 |
2013 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas.
|
23764004 |
2013 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Therefore, the aim of the study is to investigate the CNV of PI3K subunits and their relationship with clinicopathological features exploring the possible mechanism underlying of PI3K activation in DLBCL.
|
24418330 |
2014 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
PosttranslationalModification
|
disease |
BEFREE |
Moreover, we detected a similarly functioning prosurvival pathway involving phosphorylated CD19 and PI3K-dependent Erk phosphorylation in human diffuse large B-cell lymphoma cell lines.
|
24938766 |
2014 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Inhibition of the PI3K/Akt/mTOR signaling pathway in diffuse large B-cell lymphoma: current knowledge and clinical significance.
|
25215588 |
2014 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma.
|
25909227 |
2015 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Thus, our work identifies an additional mechanism of synergy between PI3K pathway inhibitors and BCL-2 antagonists that strengthens the rationale for testing this combination in DLBCL.
|
26460954 |
2015 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In the present study, we demonstrated that PF-04691502, a novel PI3K/mTOR inhibitor has potent activity in a panel of aggressive B-NHL cell lines including diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL).
|
26549638 |
2016 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Strong synergism was observed with pimasertib combined with the PI3K inhibitor idelalisib and the BTK inhibitor ibrutinib in cell lines derived from diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma.
|
26961147 |
2016 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Subsequent analyses of the roles of SPIB expression in DLBCL pathogenesis revealed that SPIB expression in lymphoma cells resulted in resistance to the BH3-mimetic ABT-263 and contributed to apoptosis resistance via the PI3K-AKT pathway.
|
27348272 |
2016 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Taken together, our study showed that PIK3CD can promote proliferation of DLBCL cells both in vitro and in vivo, suggesting that PIK3CD could be druggable in the therapy of DLBCL.
|
27448819 |
2016 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Furthermore, CUDC-907, a small-molecule dual-acting inhibitor of both class I and II HDACs and class I PI3Ks, effectively suppresses the growth and survival of MYC-altered or MYC-dependent cancer cells, such as DH DLBCL and BRD-NUT fusion-positive NUT midline carcinoma (NMC) cells, and MYC protein downregulation is an early event induced by CUDC-907 treatment.
|
27980108 |
2017 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Compared with follicular lymphoma, high PI3Kα expression was more prevalent in diffuse large B cell lymphoma (DLBCL), although both tumor types expressed substantial PI3Kδ.
|
28073005 |
2017 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.
|
28178345 |
2017 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL.
|
28202458 |
2017 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We immunohistochemically evaluated the correlation between B-cell receptor (BCR)-phosphoinositide 3-kinase (PI3K) pathway activity and MYC level in 108 cases of de-novo DLBCL, 25 of which featured loss of BCR, and investigated the effects of BCR-PI3K signalling on MYC level and phosphorylation in DLBCL cell lines.
|
28639315 |
2017 |